Navigation Links
Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
Date:10/22/2013

ANAHEIM, Calif., Oct. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar® Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome (ARDS).  The Company's Investigational New Drug (IND) application for the study has been reviewed by the U.S. Food and Drug Administration (FDA) and is now active.  ARDS is an acute life-threatening lung condition that can result from pulmonary and non-pulmonary infections or a multitude of other serious conditions. Based on our understanding of its potential mechanism of action, Questcor believes that Acthar could have both steroid-independent and steroid-dependent protective effects in this condition.

The study will seek to enroll up to 210 patients in a 4-week randomized, placebo controlled trial designed to explore the efficacy and safety of several dosing regimens of Acthar in patients with moderate to severe ARDS.  The primary objective of the study will be to determine if Acthar increases the number of ventilator-free days during the 28-day treatment period. Secondary endpoints include whether Acthar therapy diminishes mortality, organ failure and the length of hospital or ICU stay.

"Despite advances in supportive care, there are no pharmacologic therapies that address acute respiratory distress syndrome, an urgent medical condition that results in mortality rates from 25 percent to over 40 percent of patients," said Dr. David Young, Questcor's Chief Scientific Officer. "While Acthar's exact mechanism of action is unknown, based on our understanding from scientific literature and nonclinical data, we believe Acthar may be beneficial in ARDS patients via its potential anti-inflammator
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
2. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
3. Questcor to Commence Phase 2 Study of Acthar for ALS
4. Questcor to Report Second Quarter Financial Results on July 30, 2013
5. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
6. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
7. Questcor Adds Angus C. Russell to Board of Directors
8. Questcor Reports First Quarter Financial Results
9. Questcor to Report First Quarter Results on April 30, 2013
10. Questcor Reports Fourth Quarter and Full Year 2012 Results
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  ePharmaSolutions, the ... recognized as the Disruptive Innovator of the ... cloud-based eClinical platform. This solution includes an ... master file (eTMF), a remote monitoring application, ... ReferralPlus+ patient screening and matching technology. ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, ... of the National Hemophilia Foundation,s (NHF) new three-year ... support to people with hemophilia and their families/caregivers ... that can impede disease management. The curriculum for ... With Your Provider About Pain , focuses on ...
(Date:9/18/2014)... Australian biomarker discovery company Minomic International Ltd ... MiStat™ prostate cancer screening test, planning to achieve US ... Minomic,s proprietary MiStat™ technology is a screening ... biomarker known as the MIL-38 antigen. This biomarker is ... Researchers at 11 leading urology centres in ...
Breaking Medicine Technology:ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... FAIRPORT, N.Y., March 19, 2012 CooperVision, a leading ... Eighth Annual Global Awards with a "Best ... branding firm Siegel+Gale collaborated with the company on its ... is the first and highest worldwide recognition of its ...
... Therapies, Inc., a development stage biotechnology company focused on ... that it has appointed Duane Nash, MD, JD, MBA, ... Dr. Nash joins Vital Therapies, Inc., from Wedbush PacGrow ... Equity Research. According to STARMINE® / Thomson Reuters, Dr. ...
Cached Medicine Technology:CooperVision Wins 2012 REBRAND 100® Global Award 2Top Ranked Equity Analyst Joins Vital Therapies, Inc. 2
(Date:9/18/2014)... Alan Mozes HealthDay Reporter ... it comes to emergency room waiting times, patients seeking care ... staring down the clock than those seen at smaller or ... crowding and our ability to provide timely emergency care varies ... the authors of the new research, Dr. Renee Hsia, an ...
(Date:9/18/2014)... together with the Chinese Thoracic Society (CTS) announced ... CHEST World Congress 2016 will be held in ... sleep medicine from around the world are expected ... 2016. , CHEST World Congress 2016 will ... keynote addresses, presentations by leading health-care experts, and ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Qualis Health, ... has published a white paper, “Advancing Primary Care ... Health Information Technology.” , Authors Jeff Hummel, MD, ... provide guidance to organizations engaged in the work of ... health IT can bolster PCMH objectives, such as generating ...
(Date:9/18/2014)... scientists have developed a new method to study Ebola ... The Wildlife Conservation Society (WCS)-led research, published today in ... the use of fecal samples from wild great apes ... the virus. This represents a new tool for performing ... way Ebola virus is studied and improve our understanding ...
(Date:9/18/2014)... guidelines recommending that elderly men should not be routinely ... according to a new study led by researchers at ... letter online in JAMA Internal Medicine , focused ... to test for prostate cancer., "We found that the ... of elderly men in particular has been minimal at ...
Breaking Medicine News(10 mins):Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2
... in School-Age Children with Less,Complex Heart Defects, ... does not cause short-term neurological problems in,children and ... to pediatric researchers. The new finding contrasts favorably,with ... surgery for more complex heart conditions., "This ...
... U.S. Families Spend Over $3 Billion Each Year on OTC ... is about to be hit with,runny noses, sore throats and ... in the U.S. that is clinically proven to,shorten the duration ... a naturally-safe cold remedy produced by German pharmaceutical,company, Schwabe, uses ...
... ANTHEM, Ariz., Nov. 11 Prime Companies, Inc.,(Pink Sheets: ... now scheduled for launch by the end of 2008. ... consumers to search for,the dentist of their choice, who ... anticipate revenues to begin to be generated by our ...
... 11 A groundbreaking new study published in,the November ... that eaters of lower energy dense breakfast have improved ... a healthy weight. The,study found that those who enjoy ... richer in important vitamins and minerals and lower in,saturated ...
... Nov. 11 The 14th Annual National Ergonomics,Conference ... Dec. 2 - 5,will be attended by ergonomics, ... international organizations, including: American,Airlines, Bayer, CDC, ExxonMobil, Ford, ... Toyota, US Dept of Labor/OSHA, U.S.,Army and hundreds ...
... of cases, U-M Health Minute: Today,s top health issues ... Bradford Miller,has had diabetes for nine years, and he knows ... and numbness in the feet., "Knowing some of the ... care of those things immediately I knew would prevent larger,issues, ...
Cached Medicine News:Health News:No Drop in I.Q. Seen After Bypass for Child Heart Surgery 2Health News:No Drop in I.Q. Seen After Bypass for Child Heart Surgery 3Health News:Naturally Safe Cold Remedy Challenges Effectiveness of Over-The-Counter Cold Medications 2Health News:Naturally Safe Cold Remedy Challenges Effectiveness of Over-The-Counter Cold Medications 3Health News:Prime Companies Announces Launch of Consumer Dental Service Software 2Health News:Breakfast Improves Overall Diet Quality and May Help with Weight Management 2Health News:Breakfast Improves Overall Diet Quality and May Help with Weight Management 3Health News:2008 National Ergonomics Conference and Expo to Focus on Ways to Increase Productivity and Reduce Spending in the Workplace 2Health News:2008 National Ergonomics Conference and Expo to Focus on Ways to Increase Productivity and Reduce Spending in the Workplace 3Health News:Foot Problems Common Among People With Diabetes 2Health News:Foot Problems Common Among People With Diabetes 3
Patent Pending lateral flow assay platform that contributes to increased sensitivty...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 12 OD...
Medicine Products: